Table 4.
Correlation between OGG1 mutations and tumor types, ER/PR status, and HER-2/neu status in breast cancer patients.
| Mutation/exon Chr3 (GRCh37) |
Type of tumor | ER status | PR status | HER-2/neu status | |||||
|---|---|---|---|---|---|---|---|---|---|
| DCIS | IDC | ILC | −ve | +ve | −ve | +ve | −ve | +ve | |
| Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | |
| g.9792260 insert_T Intron 1 | 6 (7.69) | 24 (11.11) | 4 (10.25) | 20 (9.57) | 12 (10.62) | 28 (13.66) | 6 (4.96) | 24 (14.46) | 9 (7.44) |
| g.9793680G>A Intron 3 (rs55846930) | 9 (11.54) | 8 (3.70) | 2 (5.13) | 10 (4.78) | 9 (7.96) | 16 (7.8) | 2 (1.65) | 15 (9.14) | 4 (3.3) |
| g.9793748G>A Intron 3 | 8 (10.25) | 5 (2.31) | 1 (2.56) | 10 (4.78) | 4 (3.35) | 5 (2.43) | 9 (7.44) | 7 (4.27) | 7 (5.78) |
| g.9798336T>G Intron 5 | 00 | 6 (2.77) | 4 (10.25) | 6 (2.87) | 3 (2.65) | 8 (3.9) | 2 (1.65) | 5 (3.04) | 4 (3.3) |
| g.9798349T>A Intron 5 | 8 (10.25) | 21 (9.72) | 5 (12.82) | 18 (8.61) | 13 (11.50) | 21 (10.24) | 13 (10.74) | 16 (9.76) | 13 (10.74) |
| g.9792109delT splice site Intron 1 | 4 (5.13) | 16 (7.4) | 6 (15.38) | 16 (76.55) | 10 (10.62) | 18 (8.78) | 8 (6.61) | 17 (10.36) | 12 (9.91) |
| g.9798307T>G splice site Intron 5 | 6 (7.69) | 10 (4.63) | 00 | 9 (4.30) | 7 (6.19) | 09 (4.39) | 6 (4.96) | 8 (4.87) | 6 (4.96) |
| g.9798502T>G splice site Intron 6 | 4 (5.13) | 11 (5.09) | 3 (7.69) | 16 (76.55) | 2 (2.21) | 9 (4.39) | 9 (7.44) | 12 (7.32) | 6 (4.96) |
| g.9800972T>G splice site intron 7a | 3 (3.85) | 28 (12.96) | 1 (2.56) | 19 (9.09) | 13 (11.50) | 14 (6.82) | 16 (13.22) | 13 (7.93) | 16 (13.22) |
| g.9798848G>A 3′UTR | 00 | 30 (13.89) | 3 (7.69) | 24 (11.48) | 13 (11.50) | 16 (7.8) | 13 (10.74) | 16 (9.76) | 8 (6.61) |
| g.9798896T>C 3′UTR | 8 (10.25) | 17 (4.63) | 5 (12.82) | 29 (13.87) | 14 (12.38) | 11 (5.36) | 12 (9.91) | 15 (9.14) | 11 (9.09) |
| g.9793544T>G Exon 3, Val159Gly | 4 (5.13) | 14 (6.48) | 00 | 12 (5.65) | 6 (5.30) | 16 (7.8) | 2 (1.65) | 3 (1.83) | 12 (9.91) |
| g.9796483G>A Exon 4, Gly221Arg (TMP_ESP_3_9796483) | 5 (6.41) | 14 (6.48) | 2 (5.13) | 15 (7.18) | 5 (4.42) | 10 (4.87) | 8 (6.61) | 7 (4.27) | 6 (4.96) |
| g.9798773C>G Exon 6d Ser326Cys (rs1052133) (CM993185) | 6 (7.69) | 15 (6.94) | 1 (2.56) | 12 (5.65) | 8 (7.08) | 19 (9.27) | 3 (2.48) | 6 (3.66) | 7 (5.78) |
| g.9807669G>A Exon 8 Trp375STOP | 7 (8.97) | 4 (1.85) | 2 (5.13) | 9 (4.30) | 7 (6.19) | 5 (2.28) | 14 (11.57) | 7 (4.27) | 6 (4.96) |
| Correlationa | −0.333∗∗∗ | 0.739∗∗ | −0.155∗ | 0.318 | |||||
| p valueb | 0.0001 | 0.001 | 0.01 | 0.12 | |||||
aPearson correlation coefficient; b p value for χ 2 test; p < 0.05 is considered statistically significant; IDC: invasive ductal carcinoma; DCI: ductal carcinoma in situ; ILC: invasive lobular carcinoma; ER: estrogen receptor; PR: progesterone receptor; HER-2/nue: human epidermal growth factor receptor 2. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.